-
2025-523230-77-00
4
2026-04-27
Patients with locally advanced Basal Cell Carcinoma (LaBCC) amenable t
-
2025-523231-19-00
4
2026-04-27
Cutaneous Squamous Cell Carcinoma
-
2025-520715-13-00
4
2026-04-22
Idiopathic Pulmonary Fibrosis
-
2024-517943-29-00
5
2026-04-21
Pulmonary Hypertension associated with interstitial lung disease (WHO
-
2024-514006-31-00
9
2026-04-16
Non-active Progressive Multiple Sclerosis (PMS)
-
2025-522387-32-00
5
2026-04-10
Uveal Melanoma
-
2025-523013-28-00
4
2026-04-07
Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
-
2025-522892-27-00
4
2026-03-21
Bronchiectasis
-
2025-521884-12-00
5
2026-03-19
First line triple-negative breast cancer (TNBC)
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2025-522437-65-00
4
2026-03-06
small-cell lung cancer
-
2024-519622-20-00
1
2026-02-27
Advanced Solid Tumors Harboring RAS Mutation(S)
-
2024-519579-24-00
5
2026-02-26
Classic Congenital Adrenal Hyperplasia
-
2024-520353-21-00
3
2026-02-24
Myeloproliferative Neoplasms
-
2025-521558-40-00
5
2026-02-12
Pulmonary Hypertension Associated with Interstitial Lung Disease
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2024-520337-80-00
5
2026-01-07
Palmoplantar Pustulosis
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2025-522070-36-00
5
2025-12-15
immune thrombocytopenia (ITP)
-
2025-520794-39-00
5
2025-12-10
Arterial Hypertension
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma